Multiple Myeloma

Adam D. Cohen, MD, discusses the safety profile of ciltacabtagene autoleucel in patients with multiple myeloma, based on data from the phase 2 CARTITUDE-2 study.

Jason Brayer, MD, PhD, discusses the promise of bispecific T-cell engagers in multiple myeloma.

A proportion of patients with multiple myeloma receiving CD38-directed and BCMA-directed therapies had a lack of T-cell responses and an absence of anti–SARS-CoV-2 Spike antibodies following SARS-CoV-2 vaccination, underscoring the need for serological testing after vaccination to identify these patients.

Brandon Blue, MD, discusses the importance of early intervention in relapsed/refractory multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses investigational strategies to mitigate belantamab mafodotin-blmf–related keratopathy in multiple myeloma.

Nina Shah, MD, discusses the potential utility of natural killer cells in multiple myeloma.

Oncopeptides AB has made the decision to withdraw the indication of melphalan flufenamide in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.

Doris Hansen, MD, discusses the utilization of BCMA-directed therapy in multiple myeloma.

Jason Brayer, MD, PhD, discusses the emergence of bispecific T-cell engagers and bispecific antibodies in multiple myeloma.

Irene Ghobrial, MD, discusses future efforts to prevent the development of multiple myeloma. 

Omar Castaneda Puglianini, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses next steps with CAR T-cell therapy in penta-refractory multiple myeloma.

Brandon Blue, MD, discusses treatment considerations for patients with relapsed/refractory multiple myeloma.

Jason Brayer, MD, PhD, discusses bispecific antibodies and T-cell engagers as alternative options to CAR T-cell therapy in patients with multiple myeloma. 

Doris Hansen, MD, discusses the promise of ALLO-715 in relapsed/refractory multiple myeloma. Scroll to 0:07 in the video for Dr. Hansen's topline points on the agent.

Irene Ghobrial, MD, discusses the key objectives of the PROMISE study in multiple myeloma.

Muhamed Baljevic, MD, discusses the current limitations of CAR T-cell therapy in multiple myeloma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses mitigating belantamab mafodotin-blmf–related keratopathy in relapsed/refractory multiple myeloma.

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Doris Hansen, MD, discusses the progression-free survival benefit yielded by idecabtagene vicleucel on the phase 2 KarMMa trial in patients with pretreated relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, discusses the methods utilized in the phase 2 KarMMa trial in multiple myeloma.

Omar Castaneda Puglianini, MD, discusses results from the phase 1b/2 CARTITUDE-1 trial evaluating ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma. 

Rachid Baz, MD, discusses the role of alkylating agents in relapsed/refractory multiple myeloma.

Brandon Blue, MD, discusses the utility of carfilzomib in relapsed/refractory multiple myeloma.

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.